Use of Potentially Inappropriate Medications in People With Dementia in Vietnam and Its Associated Factors

Nguyen, Tuan Anh; Pham, Thang; Vu, Huyen Thi Thanh; Nguyễn, Thanh Xuân; Vu, Trinh Thi; Nguyễn, Bình Thị Thanh; Nguyen, Ngoc Quynh; Nguyen, Binh Thanh; Nguyen, Tam Ngoc; Phan, Sinh Viet; Nguyen, Anh Trung; Pham, Tuan Le; Dang, Thu Ha; Ellett, Lisa M. Kalisch; Gillam, Marianne; Pratt, Nicole; Sun, Qiang; Wang, Haipeng; Kanjanarach, Tipaporn; Hassali, Mohamed Azmi; Babar, Zaheer‐Ud‐Din; Razak, Asrenee Ab; Chinwong, Dujrudee; Roughead, Elizabeth E.

doi:10.1177/1533317518768999

Cited by 14 publications

(10 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After removing duplication (n = 1,302), 4,337 records were used to screen the title and abstract. Finally, 62 studies (Zuckerman et al, 2005;Raivio et al, 2006;Holmes et al, 2008;Chan et al, 2009;Lau et al, 2010;Somers et al, 2010;Tjia et al, 2010;Andersen et al, 2011;Lau et al, 2011;Bosboom et al, 2012;Colloca et al, 2012;Parsons et al, 2012;Thorpe et al, 2012;Fiss et al, 2013;Koyama et al, 2013;Montastruc et al, 2013;Toscani et al, 2013;Tjia et al, 2014;Hanlon et al, 2015;Skoldunger et al, 2015;Barry et al, 2016;Cross et al, 2016;Walsh et al, 2016;Chuang et al, 2017;Clague et al, 2017;Hyttinen et al, 2017;Kanagaratnam et al, 2017;Oesterhus et al, 2017;Ramsey et al, 2017;Wucherer et al, 2017;Kristensen et al, 2018;Nguyen et al, 2018;Renom-Guiteras et al, 2018;Bala et al, 2019;Brimelow et al, 2019;Denholm et al, 2019;Eshetie et al, 2019a;Kristensen et al, 2019;Soysal et al, 2019;Eshetie et al, 2020;Eshetie et al...…”

Section: Study Selectionmentioning

confidence: 99%

“…Of all included studies, 53 studies reported the prevalence of PIM (Zuckerman et al, 2005;Raivio et al, 2006;Holmes et al, 2008; Frontiers in Pharmacology frontiersin.org Frontiers in Pharmacology frontiersin.org conducted in South America (Forgerini et al, 2020;Ferreira et al, 2021), and the rest of the studies conducted in Oceania (Somers et al, 2010;Bosboom et al, 2012;Cross et al, 2016;Bala et al, 2019;Eshetie et al, 2019b;Brimelow et al, 2019;Eshetie et al, 2020;Eshetie et al, 2020;Ruangritchankul et al, 2020;Thapaliya et al, 2021) (n = 10), North America (Zuckerman et al, 2005;Holmes et al, 2008;Chan et al, 2009;Lau et al, 2010;Tjia et al, 2010;Lau et al, 2011;Thorpe et al, 2012;Koyama et al, 2013;Tjia et al, 2014;Hanlon et al, 2015;Ramsey et al, 2017;Growdon et al, 2021;Vickers et al, 2021;Bae-Shaaw et al, 2023;Ryskina et al, 2023) (n = 15), and Asia (Chuang et al, 2017;Nguyen et al, 2018;Chao et al, 2022;Yoon et al, 2022;Zhao et al, 2022) (n = 5). Table 1 presents the characteristics of the included studies.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Regarding gender, a total of thirteen studies (Colloca et al, 2012;Fiss et al, 2013;Montastruc et al, 2013;Barry et al, 2016;Chuang et al, 2017;Hyttinen et al, 2017;Oesterhus et al, 2017;Nguyen et al, 2018;Murphy et al, 2020;Ferreira et al, 2021;Rangfast et al, 2022;Yoon et al, 2022;Zhao et al, 2022) were pooled to explore the Note that with <3 studies, the distribution is inestimable and hence not displayed.…”

Section: Factors Associated With Potentially Inappropriate Medicationsmentioning

confidence: 99%

See 2 more Smart Citations

Global prevalence of polypharmacy and potentially inappropriate medication in older patients with dementia: a systematic review and meta-analysis

Zhao,

Chen,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Older patients with dementia always need multiple drugs due to comorbidities and cognitive impairment, further complicating drug treatment and increasing the risk of potentially inappropriate medication. The objective of our study is to estimate the global prevalence of polypharmacy and potentially inappropriate medication (PIM) and explore the factors of PIM for older patients with dementia.Methods: We searched PubMed, Embase (Ovid), and Web of Science databases to identify eligible studies from inception to 16 June 2023. We conducted a meta-analysis for observational studies reporting the prevalence of potentially inappropriate medication and polypharmacy in older patients with dementia using a random-effect model. The factors associated with PIM were meta-analyzed.Results: Overall, 62 eligible studies were included, of which 53 studies reported the prevalence of PIM and 28 studies reported the prevalence of polypharmacy. The pooled estimate of PIM and polypharmacy was 43% (95% CI 38–48) and 62% (95% CI 52–71), respectively. Sixteen studies referred to factors associated with PIM use, and 15 factors were further pooled. Polypharmacy (2.83, 95% CI 1.80–4.44), diabetes (1.31, 95% CI 1.04–1.65), heart failure (1.17, 95% CI 1.00–1.37), depression (1.45, 95% CI 1.14–1.88), history of cancer (1.20, 95% CI 1.09–1.32), hypertension (1.46, 95% CI 1.05–2.03), ischemic heart disease (1.55, 95% CI 0.77–3.12), any cardiovascular disease (1.11, 95% CI 1.06–1.17), vascular dementia (1.09, 95% CI 1.03–1.16), chronic obstructive pulmonary disease (1.39, 95% CI 1.13–1.72), and psychosis (1.91, 95% CI 1.04–3.53) are positively associated with PIM use.Conclusion: PIM and polypharmacy were highly prevalent in older patients with dementia. Among different regions, the pooled estimate of PIM use and polypharmacy varied widely. Increasing PIM in older patients with dementia was closely associated with polypharmacy. For other comorbidities such as heart failure and diabetes, prescribing should be cautioned.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Factors Associated With Potentially Inappropriate Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Global prevalence of polypharmacy and potentially inappropriate medication in older patients with dementia: a systematic review and meta-analysis

Zhao,

Chen,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The prevalence of cognitive symptoms of dementia in adults aged 60 years and above is relatively high in Vietnam (14.4-46.4%) 23,24 with an estimated 2.4 million people living with dementia in Vietnam by 2050. 25 Advancing the mental health of older people in Vietnam is critical in the face of population growth and increased living standards resulting in longer lifespan. In the first Vietnam National Dementia Conference, dementia was recognized as a public health priority in Vietnam.…”

Section: Introductionmentioning

confidence: 99%

A Multidomain Intervention Program for Older People with Dementia: A Pilot Study

Nguyễn¹,

Vu²,

Nguyen³

et al. 2023

OAJCT

View full text Add to dashboard Cite

Background: Multidomain interventions have been shown to be effective in improving cognition, quality of life, reducing neuropsychiatric symptoms and delaying progression of functional impairment or disability in dementia patients. To investigate the multidomain intervention in other populations and diverse cultural and geographical settings, this pilot study will assess the feasibility of a multidomain intervention for older people with dementia in nursing homes in Vietnam. Methods: Participants will be randomized into two equal groups, to receive either a multidomain intervention (intervention group) or regular health advice (control group). The intervention will include physical, cognitive, and social interventions as well as management of metabolic and vascular risk factors. We will hypothesize that the multidomain intervention will be feasible in Vietnam, and participants who receive the intervention will show improvement in quality of life, behaviors, functional ability, cognitive function, sleep, and in reduction of falls, use of healthcare services, and death rate compared to those in the control group during the 6 months intervention period and after the 6 months extended follow-up. Discussion: This is the first study to evaluate the feasibility of a multidomain intervention program for older people with dementia in nursing homes in Vietnam. The results from the trial will inform clinicians and the public of the possibility of comprehensive treatment beyond simply drug treatments for dementia. This paves the way for further studies to evaluate the long-term effects of multidomain interventions in dementia patients. Furthermore, the research results will provide information on the effectiveness of multidomain interventions which will inform policy development on dementia. Trial Registration: The trial is registered with ClinicalTrials.gov identifier: NCT04948450 on 02/07/2021.

show abstract

“…Approximately 60% of people with dementia live in low- and middle-income countries (LMICs) and the costs of care are mostly borne by family members [ 2 ]. Health and social care systems in LMICs are often not well-developed or well-funded, resulting in unmet care needs for people with dementia and their carers [ 3 , 4 ]. In high-income countries (HICs), most people with dementia also live at home and receive care from their families [ 3 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Empowering Dementia Carers With an iSupport Virtual Assistant (e-DiVA) in Asia-Pacific Regional Countries: Protocol for a Pilot Multisite Randomized Controlled Trial

Nguyen¹,

Tran²,

Esterman³

et al. 2021

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

Background Dementia is a global public health priority with an estimated prevalence of 150 million by 2050, nearly two-thirds of whom will live in the Asia-Pacific region. Dementia creates significant care needs for people with the disease, their families, and carers. iSupport is a self-help platform developed by the World Health Organization (WHO) to provide education, skills training, and support to dementia carers. It has been adapted in some contexts (Australia, India, the Netherlands, and Portugal). Carers using the existing adapted versions have identified the need to have a more user-friendly version that enables them to identify solutions for immediate problems quickly in real time. The iSupport virtual assistant (iSupport VA) is being developed to address this gap and will be evaluated in a randomized controlled trial (RCT). Objective This paper reports the protocol of a pilot RCT evaluating the iSupport VA. Methods Seven versions of iSupport VA will be evaluated in Australia, Indonesia, New Zealand, and Vietnam in a pilot RCT. Feasibility, acceptability, intention to use, and preliminary impact on carer-perceived stress of the iSupport VA intervention will be assessed. Results This study was funded by the e-ASIA Joint Research Program in November 2020. From January to July 2023, we will enroll 140 dementia carers (20 carers per iSupport VA version) for the pilot RCT. The study has been approved by the Human Research Committee, University of South Australia, Australia (203455). Conclusions This protocol outlines how a technologically enhanced version of the WHO iSupport program—the iSupport VA—will be evaluated. The findings from this intervention study will provide evidence on the feasibility and acceptability of the iSupport VA intervention, which will be the basis for conducting a full RCT to assess the effectiveness of the iSupport VA. The study will be an important reference for countries planning to adapt and enhance the WHO iSupport program using digital health solutions. Trial Registration Australian New Zealand Clinical Trials Registry ACTRN12621001452886; https://tinyurl.com/afum5tjz International Registered Report Identifier (IRRID) PRR1-10.2196/33572

show abstract

Use of Potentially Inappropriate Medications in People With Dementia in Vietnam and Its Associated Factors

Cited by 14 publications

References 53 publications

Global prevalence of polypharmacy and potentially inappropriate medication in older patients with dementia: a systematic review and meta-analysis

Global prevalence of polypharmacy and potentially inappropriate medication in older patients with dementia: a systematic review and meta-analysis

A Multidomain Intervention Program for Older People with Dementia: A Pilot Study

Empowering Dementia Carers With an iSupport Virtual Assistant (e-DiVA) in Asia-Pacific Regional Countries: Protocol for a Pilot Multisite Randomized Controlled Trial

Contact Info

Product

Resources

About